What is Bristol-myers Squibb Co. share price today?

Bristol-myers Squibb Co. (BMY) share price today is {{live_price}}.

Can Indians buy Bristol-myers Squibb Co. shares?

Yes, Indians can invest in the Bristol-myers Squibb Co. (BMY) from India. With INDmoney, you can buy Bristol-myers Squibb Co. at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Bristol-myers Squibb Co. at zero transaction cost.

How can I buy Bristol-myers Squibb Co. shares from India?

It is very easy to buy Bristol-myers Squibb Co. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bristol-myers Squibb Co. be purchased?

Yes, you can buy fractional shares of Bristol-myers Squibb Co. with INDmoney app.

What are the documents required to start investing in Bristol-myers Squibb Co. stocks?

To start investing in Bristol-myers Squibb Co., You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Bristol-myers Squibb Co.

Today’s highest price of Bristol-myers Squibb Co. (BMY) is {{1_rba_end}}. Today’s lowest price of Bristol-myers Squibb Co. (BMY) is {{1_rba_st}}.

What is today's market capitalisation of Bristol-myers Squibb Co.

Today's market capitalisation of Bristol-myers Squibb Co. BMY is 105.8B

What is the 52 Week High and Low Range of Bristol-myers Squibb Co.

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Bristol-myers Squibb Co. is down from its 52 Week High?

Bristol-myers Squibb Co. (BMY) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Bristol-myers Squibb Co. is up from its 52 Week low?

Bristol-myers Squibb Co. (BMY) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Bristol-myers Squibb Co.?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Bristol-myers Squibb Co.

Dr. Christopher S. Boerner Ph.D. is the current Chief Executive Officer (CEO) of Bristol-myers Squibb Co..

Home>
US Stocks>
Bristol-myers Squibb Co.

Bristol-myers Squibb Co. (BMY)

$52.2

-0.2

(-0.38%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Performance

$52.01
$52.65
$52.20
0.36%
Downside
Day's Volatility :1.21%
Upside
0.85%
$39.35
$57.65
$52.20
24.62%
Downside
52 Weeks Volatility :31.74%
Upside
9.45%

Returns

Period	Bristol-myers Squibb Co.	Sector (Health Care)	S&P500
3 Months	30.01%	3.8%	3.6%
6 Months	7.61%	10.8%	13.5%
1 Year	-7.56%	18.2%	34.4%
3 Years	-8.53%	22.6%	33.3%

Highlights

Market Capitalization	105.8B
Book Value	$8.39
Dividend Share	2.37
Dividend Yield	4.58%
Earnings Per Share (EPS)	-3.25
PEG Ratio	2.04
Wall Street Target Price	52.77

Profit Margin	-14.06%
Operating Margin TTM	21.29%

Return On Assets TTM	6.0%
Return On Equity TTM	-26.59%

Revenue TTM	46.5B
Revenue Per Share TTM	22.87
Quarterly Revenue Growth YOY	8.7%
Gross Profit TTM	36.4B
EBITDA	19.0B
Diluted Eps TTM	-3.25
Quarterly Earnings Growth YOY	-0.16

EPS Estimate Current Year	0.74
EPS Estimate Next Year	6.97
EPS Estimate Current Quarter	1.63
EPS Estimate Next Quarter	1.65

Analyst Recommendation

Hold

32%Buy

64%Hold

3%Sell

Based on 31 Wall street analysts offering stock ratings for Bristol-myers Squibb Co.(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 1.09%

Current $52.20

Target $52.77

Company Financials

	FY18	Y/Y Change
Revenue	22.6B	↑ 8.59%
Net Income	5.0B	↑ 391.76%
Net Profit Margin	21.95%	↑ 17.1%

	FY19	Y/Y Change
Revenue	26.1B	↑ 15.89%
Net Income	3.4B	↓ 30.55%
Net Profit Margin	13.15%	↓ 8.8%

	FY20	Y/Y Change
Revenue	42.5B	↑ 62.62%
Net Income	-9.0B	↓ 361.56%
Net Profit Margin	-21.16%	↓ 34.31%

	FY21	Y/Y Change
Revenue	46.4B	↑ 9.09%
Net Income	7.0B	↓ 177.75%
Net Profit Margin	15.08%	↑ 36.24%

	FY22	Y/Y Change
Revenue	46.2B	↓ 0.49%
Net Income	6.3B	↓ 9.54%
Net Profit Margin	13.71%	↓ 1.37%

	FY23	Y/Y Change
Revenue	45.0B	↓ 2.5%
Net Income	8.0B	↑ 26.84%
Net Profit Margin	17.83%	↑ 4.12%

	Q1 FY23	Q/Q Change
Revenue	11.3B	↓ 0.6%
Net Income	2.3B	↑ 11.87%
Net Profit Margin	19.95%	↑ 2.22%

	Q2 FY23	Q/Q Change
Revenue	11.2B	↓ 0.98%
Net Income	2.1B	↓ 8.36%
Net Profit Margin	18.47%	↓ 1.48%

	Q3 FY23	Q/Q Change
Revenue	11.0B	↓ 2.32%
Net Income	1.9B	↓ 6.99%
Net Profit Margin	17.58%	↓ 0.89%

	Q4 FY23	Q/Q Change
Revenue	11.5B	↑ 4.66%
Net Income	1.8B	↓ 8.61%
Net Profit Margin	15.35%	↓ 2.23%

	Q1 FY24	Q/Q Change
Revenue	11.9B	↑ 3.38%
Net Income	-11.9B	↓ 775.99%
Net Profit Margin	-100.39%	↓ 115.74%

	Q2 FY24	Q/Q Change
Revenue	12.2B	↑ 2.83%
Net Income	1.7B	↓ 114.1%
Net Profit Margin	13.77%	↑ 114.16%

	FY18	Y/Y Change
Total Assets	10.7B	↓ 68.23%
Total Liabilities	7.3B	↓ 66.14%

	FY19	Y/Y Change
Total Assets	129.9B	↑ 1119.1%
Total Liabilities	78.2B	↑ 964.72%

	FY20	Y/Y Change
Total Assets	118.5B	↓ 8.82%
Total Liabilities	80.6B	↑ 3.01%

	FY21	Y/Y Change
Total Assets	109.3B	↓ 7.74%
Total Liabilities	73.3B	↓ 9.05%

	FY22	Y/Y Change
Total Assets	96.8B	↓ 11.43%
Total Liabilities	65.7B	↓ 10.38%

	FY23	Y/Y Change
Total Assets	95.2B	↓ 1.72%
Total Liabilities	65.7B	↓ 0.04%

	Q1 FY23	Q/Q Change
Total Assets	94.3B	↓ 2.62%
Total Liabilities	62.4B	↓ 5.03%

	Q2 FY23	Q/Q Change
Total Assets	93.5B	↓ 0.84%
Total Liabilities	61.5B	↓ 1.5%

	Q3 FY23	Q/Q Change
Total Assets	91.3B	↓ 2.38%
Total Liabilities	62.2B	↑ 1.21%

	Q4 FY23	Q/Q Change
Total Assets	95.2B	↑ 4.27%
Total Liabilities	65.7B	↑ 5.58%

	Q1 FY24	Q/Q Change
Total Assets	99.0B	↑ 4.07%
Total Liabilities	82.5B	↑ 25.59%

	Q2 FY24	Q/Q Change
Total Assets	94.6B	↓ 4.43%
Total Liabilities	77.6B	↓ 5.95%

	FY18	Y/Y Change
Operating Cash Flow	5.9B	↑ 12.61%
Investing Cash Flow	-874.0M	↑ 1224.24%
Financing Cash Flow	-3.5B	↓ 13.29%

	FY19	Y/Y Change
Operating Cash Flow	8.1B	↑ 35.81%
Investing Cash Flow	-9.8B	↑ 1017.85%
Financing Cash Flow	7.6B	↓ 315.59%

	FY20	Y/Y Change
Operating Cash Flow	14.1B	↑ 74.19%
Investing Cash Flow	-10.9B	↑ 11.15%
Financing Cash Flow	-1.2B	↓ 115.1%

	FY21	Y/Y Change
Operating Cash Flow	16.2B	↑ 15.34%
Investing Cash Flow	-538.0M	↓ 95.05%
Financing Cash Flow	-16.2B	↑ 1309.56%

	FY22	Y/Y Change
Operating Cash Flow	13.1B	↓ 19.38%
Investing Cash Flow	-1.1B	↑ 97.4%
Financing Cash Flow	-17.0B	↑ 4.55%

	FY23	Y/Y Change
Operating Cash Flow	13.9B	↑ 6.08%
Investing Cash Flow	-2.3B	↑ 116.1%
Financing Cash Flow	-9.4B	↓ 44.49%

	Q1 FY23	Q/Q Change
Operating Cash Flow	3.0B	↓ 10.16%
Investing Cash Flow	-210.0M	↓ 117.31%
Financing Cash Flow	-3.1B	↓ 6.04%

	Q2 FY23	Q/Q Change
Operating Cash Flow	1.9B	↓ 36.46%
Investing Cash Flow	-329.0M	↑ 56.67%
Financing Cash Flow	-2.2B	↓ 28.75%

	Q3 FY23	Q/Q Change
Operating Cash Flow	4.8B	↑ 151.78%
Investing Cash Flow	-410.0M	↑ 24.62%
Financing Cash Flow	-5.2B	↑ 137.46%

	Q4 FY23	Q/Q Change
Operating Cash Flow	4.3B	↓ 10.5%
Investing Cash Flow	-1.3B	↑ 228.29%
Financing Cash Flow	967.0M	↓ 118.74%

	Q1 FY24	Q/Q Change
Operating Cash Flow	2.8B	↓ 33.35%
Investing Cash Flow	-19.6B	↑ 1357.5%
Financing Cash Flow	14.6B	↑ 1414.37%

Technicals Summary

Sell

Neutral

Buy

Bristol-myers Squibb Co. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bristol-myers Squibb Co.	6.25%	7.61%	-7.56%	-8.53%	1.24%
Eli Lilly And Company	0.9%	24.15%	53.0%	294.21%	763.82%
Johnson & Johnson	-2.45%	9.4%	2.94%	1.42%	23.52%
Merck & Co. Inc.	-5.29%	-13.04%	5.5%	38.99%	29.57%
Abbvie Inc	-0.01%	20.12%	31.24%	78.93%	163.27%
Amgen Inc.	-1.23%	23.67%	15.58%	61.26%	61.84%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bristol-myers Squibb Co.	12.66	NA	2.04	0.74	-0.27	0.06	0.05	8.39
Eli Lilly And Company	114.93	114.93	0.86	15.83	0.59	0.14	0.01	15.06
Johnson & Johnson	24.93	24.93	0.97	10.03	0.22	0.08	0.03	29.72
Merck & Co. Inc.	20.32	20.32	0.07	7.93	0.33	0.11	0.03	17.19
Abbvie Inc	65.0	65.0	0.46	10.87	0.54	0.08	0.03	3.84
Amgen Inc.	56.51	56.51	2.23	19.49	0.49	0.04	0.03	11.03

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bristol-myers Squibb Co.	Hold	$105.8B	1.24%	12.66	-14.06%
Eli Lilly And Company	Buy	$839.3B	763.82%	114.93	18.86%
Johnson & Johnson	Buy	$396.8B	23.52%	24.93	43.91%
Merck & Co. Inc.	Buy	$278.1B	29.57%	20.32	21.99%
Abbvie Inc	Buy	$343.3B	163.27%	65.0	9.71%
Amgen Inc.	Buy	$176.4B	61.84%	56.51	10.12%

Insights on Bristol-myers Squibb Co.

Increasing Revenue
Revenue is up for the last 4 quarters, 10.96B → 12.20B (in $), with an average increase of 3.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -11.91B → 1.68B (in $), with an average increase of 809.0% per quarter
Vs LLY
In the last 1 year, Eli Lilly And Company has given 53.0% return, outperforming this stock by 60.6%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 294.2% return, outperforming this stock by 302.7%

Institutional Holdings

Vanguard Group Inc
9.20%
BlackRock Inc
7.83%
State Street Corp
4.51%
JPMorgan Chase & Co
3.68%
Charles Schwab Investment Management Inc
2.91%
Capital Research & Mgmt Co - Division 3
2.73%

Corporate Announcements

Bristol-myers Squibb Co. Dividends March,2024
In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.6
Read More

Organization	Bristol-myers Squibb Co.
Employees	34100
CEO	Dr. Christopher S. Boerner Ph.D.
Industry	Health Technology

Bristol-myers Squibb Co. (BMY)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Increasing Revenue

Increasing Net Profit

Vs LLY

Vs LLY

Institutional Holdings

Corporate Announcements

Bristol-myers Squibb Co. Dividends March,2024

Company Information

Discover More

FAQs